NEW YORK: La Jolla Pharmaceutical Co said on Monday its lead experimental drug to treat low blood pressure met the main goal of a late-stage study on patients with distributive shock who had not adequately responded to existing treatments. Distributive shock is a state in which the heart is pumping well enough, but the blood is not distributed properly to the vital organs, leading to severe hypotention. The drug, LJPC-501, is La Jolla’s formulation of a natural peptide that regulates...